Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is conducting a Phase 4 clinical trial titled ‘A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.’ The study aims to assess the long-term safety of avacopan, a treatment for ANCA-associated vasculitis, a serious autoimmune disease.
The study tests avacopan, an oral drug, in combination with standard immunosuppressive therapy. Participants are divided into three groups: one receiving avacopan for five years, another receiving avacopan for one year followed by a placebo, and a third group receiving a placebo for five years.
This interventional study is randomized with a parallel assignment model and double masking for participants and investigators. Its primary purpose is treatment-focused, aiming to provide insights into the long-term safety of avacopan.
The study began on February 7, 2024, with a primary completion date yet to be announced. The last update was submitted on August 20, 2025, indicating ongoing progress.
This update could positively impact Amgen’s stock performance by reinforcing investor confidence in the company’s pipeline. The study’s outcome may influence the competitive landscape in autoimmune disease treatments, potentially affecting competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.